|
|
Study Of Revlimid And Vidaza In Higher-Risk MDS Is Well-Tolerated And Has High Activity (Medical News Today) |
 |
 |
|
Celgene International Sarl (NASDAQ: CELG) reported that results of a Phase I study combining REVLIMID and VIDAZA in patients with higher-risk myelodysplastic syndromes (MDS) found that the combination of these two therapies is well tolerated and has high activity. The data were reported during the 50th Annual Meeting of the American Society of Hematology. read more |
|
|
Citing a Lack of Funds, PLC Systems Defers RenalGuard Trial - OneMedPlace |
|
|
|
CIN is a growing concern due to the increasing number of older patients, diabetics and patients with pre-existing renal failure. They are at increased risk ... read more |
|
High phosphorus linked to coronary calcification in CKD - NephrOnline |
|
|
|
... contribute to the increased risk of cardiovascular disease in patients with CKD, reports a study in the Journal of the American Society of Nephrology. ... read more |
|
|
Patient who contracted MRSA after routine hip operation is slapped ... - Daily Mail |
|
|
|
... doctors found the infection was more serious than first thought, with Mr Hogan suffering from acute septicaemia and renal failure. ... read more |
|
Novartis International AG (VTX:NOVN) Glivec Receives US Approval ... - ABN Newswire (press release) |
|
|
|
... pancreatitis, hepatic failure, exfoliative dermatitis, angioedema, Stevens-Johnson syndrome, renal failure, fluid retention, edema (including brain, ... read more |
|
|
|
|
<< Start < Prev 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 Next > End >>
|
|
Page 2601 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
